Enterprise Value

150.7M

Cash

96.52M

Avg Qtr Burn

-11.42M

Short % of Float

5.41%

Insider Ownership

20.83%

Institutional Own.

55.83%

Qtr Updated

06/30/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Soticlestat (OV935) Details
Dravet syndrome, Rare diseases, Rare genetic disease

Phase 3

Update

Phase 1

Data readout

OV101 (δ-selective GABAA receptor agonist) (gaboxadol) Details
Genetic disorder, Rare genetic disease, Angelman Syndrome

Failed

Discontinued

OV101 (gaboxadol) Details
Rare genetic disease, Fragile X syndrome

Failed

Discontinued

OV935 (CH24H Inhibitor) Details
Rare diseases, Cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder, Rare genetic disease

Failed

Discontinued